Submissions from 2024
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study., Zoe Swank, Ella Borberg, Yulu Chen, Yasmeen Senussi, Sujata Chalise, Zachary Manickas-Hill, Xu G Yu, Jonathan Z Li, Galit Alter, Timothy J Henrich, J Daniel Kelly, Rebecca Hoh, Sarah A Goldberg, Steven G Deeks, Jeffrey N Martin, Michael J Peluso, Aarthi Talla, Xiaojun Li, Peter Skene, Thomas F Bumol, Troy R Torgerson, Julie L Czartoski, M Juliana McElrath, Elizabeth W Karlson, David R Walt, RECOVER consortium authors, and Katherine Tuttle (RECOVER consortium authors)
A Microfluidic, Multi-Antibody Cell Capture Method to Evaluate Tumor Cells in Cerebrospinal Fluid in Patients With Suspected Leptomeningeal Metastases., Nathan T Sweed, Hao-Ching Hsiao, Barbara Blouw, Tony J Pircher, Deanna Fisher, Katrina Rose Naluz, Julie Ann Mayer, Michael C Dugan, Akanksha Sharma, Jose Carrillo, and Santosh Kesari
Case Report: A Nurses Experience with a Surgical Site Infection (SSI); Lessons from the Frontlines, Anna Tabor, Rachel Tommeraasen, and Joshua E Drumm
Case Presentation, Lori Tam
Sex Differences in SCAD: Insights from the iSCAD Registry, Lori Tam
Sex differences in Spontaneous Coronary Artery Dissection: A Report of the iSCAD Registry, Lori Tam, Sahar Naderi, Malissa J. Wood, Gerald Chi, Heather L. Gornik, Bryan J. Wells, Daniella Kadian-Dodov, Anna Grodzinsky, Angela Taylor, Connie Ng Hess, Jennifer Lewey, Stanislav Henkin, James Langley Orford, Kathryn Lindley, Gretchen L. Wells, Rina Mauricio, C. Miachel Gibson, Katherine Leon, and Soo Hyun Kim
Development of a Diagnostic Model for Pancreatic Ductal Adenocarcinoma Using Machine Learning and Blood-Based miRNAs., Jason Y Tang, Valentina L Kouznetsova, Santosh Kesari, and Igor F Tsigelny
Bilateral hip DXA Reporting: 2023 Official Positions of the International Society for Clinical Densitometry., S Bobo Tanner, Diane Krueger, Auryan Szalat, Tyler Prout, Adrian Lau, Alan Malabanan, Harold Rosen, and Christopher Shuhart
Don't anchor on me!, Ann-Marie Tantoco, Ajay Bhasin, Maria Santos, Art Kastl, and Adam Bracken
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors., Matthew H Taylor, Aung Naing, John Powderly, Paul Woodard, Luke Chung, Wen Hong Lin, Hongyu Tian, Nathan Siemers, Hong Xiang, Rong Deng, Kyu Hong, Donna Valencia, Tao Huang, Ying Zhu, X Charlene Liao, Xiao Min Schebye, and Manish R Patel
Sepsis Transitional Care Management: Could a Phone Call Change a Life?, Linh Taylor, MD
Hydroxocobalamin in Septic Shock Management: Should it Be Introduced Sooner?, Linh Tang Taylor, MD; Cameron Miles Long, MD; and Omar Pandhair, MD
COVID-19 Vaccine Related Cervical Radiculitis and Parsonage-Turner Syndrome: Case Report and Review of the Literature., Zachary C Taylor, Ravi S Nunna, Angela Tran, Matias Costa, Maxwell Gruber, Periklis Godolias, and Zachary Litvack
Non-immune hydrops fetalis is associated with bi-allelic pathogenic variants in the MYB Binding Protein 1a (MYBBP1A) gene., Jair Tenorio-Castano, Elena Mansilla Aparicio, Fe Amalia García Santiago, Cherise M Klotz, Rita María Regojo, Estefanía Anguita, Erin Ryan, Jane Juusola, Beatriz Herrero, Pedro Arias, Alejandro Parra, Patricia Pascual, Natalia Gallego, Mario Cazalla, Roberto Rodriguez-González, Eugenia Antolín, Julián Nevado, Víctor L Ruiz-Perez, and Pablo Lapunzina
Increasing the Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease, Amanda Tep, DO; Jason Heino, DO; Shelley Schoepflin Sanders, MD; and Alyssa Nelson
Increasing the Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease, Amanda Tep, DO and Fawn Wolf, MD
Thrombectomy for Stroke With Large Infarct on Noncontrast CT: The TESLA Randomized Clinical Trial., Writing Committee for the TESLA Investigators, Albert J Yoo, Osama O Zaidat, Sunil A Sheth, Ansaar T Rai, Santiago Ortega-Gutierrez, Curtis A Given, Syed F Zaidi, Ramesh Grandhi, Hugo Cuellar, Maxim Mokin, Jeffrey M Katz, Amer Alshekhlee, Muhammad A Taqi, Sameer A Ansari, Adnan H Siddiqui, Nobl Barazangi, Joey D English, Alberto Maud, Jawad Kirmani, Rishi Gupta, Dileep R Yavagal, Jason Tarpley, Dhruvil J Pandya, Marshall C Cress, Sushrut Dharmadhikari, Kaiz S Asif, Tareq Kass-Hout, Ajit S Puri, Nazli Janjua, Aniel Q Majjhoo, Aamir Badruddin, Randall C Edgell, Rakesh Khatri, Larry Morgan, Anmar Razak, Alicia Zha, Priyank Khandelwal, Nils Mueller-Kronast, Dennis J Rivet, Thomas Wolfe, Brian Snelling, Ali Sultan-Qurraie, Shao-Pow Lin, Rajkamal Khangura, Alejandro M Spiotta, Parita Bhuva, Sergio Salazar-Marioni, Eugene Lin, Abdul R Tarabishy, Edgar A Samaniego, Murali K Kolikonda, Mouhammad A Jumaa, Vivek K Reddy, Pankaj Sharma, Olvert A Berkhemer, Pieter-Jan van Doormaal, Adriaan C G M van Es, Wim H van Zwam, Bart J Emmer, Ludo F Beenen, Charles B L M Majoie, Nancy Buderer, Michelle A Detry, Anna Bosse, Todd L Graves, Christina Saunders, Lucas Elijovich, Ashutosh Jadhav, Mary Patterson, Hannah Slight, Kristine Below, Sami Al Kasab, and TESLA Investigators
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors, Jacob Stephen Thomas, Matthew H Taylor, and See full list of authors in comments
Updated results from a phase 1 study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumorsv, J Thomas, Matthew Taylor, and See full list of authors in comments
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors, Sajeve Samuel Thomas and Rom Leidner
Atherosclerosis in ancient mummified humans: the global HORUS study., Randall C Thompson, M Linda Sutherland, Adel H Allam, Alice Paladin, Albert R Zink, L Samuel Wann, James D Sutherland, Bruno Frohlich, David Hunt, Michael I Miyamoto, Christopher J Rowan, David E Michalik, Caleb E Finch, Guido P Lombardi, Muhammad Al-Tohamy Soliman, Janet M Monge, Clide M Vallodolid, Samantha L Cox, Gomaa Abdel-Maksoud, Ibrahim Badr, Abd El-Halim Nur El-Din, Samantha I King, Friederike Seyfried, Stephanie Panzer, Stephanie Zesch, Christina Wurst, Marco Samadelli, Giulia Gregori, Marco Rossani, Guido Valverde, Frank Maixner, Federica Facchetti, Scott Warnasch, Lucia Watson, Jagat Narula, Andrew J Nelson, and Gregrory S Thomas
ARISE I Consensus Review on the Management of Intracranial Aneurysms., Stavropoula I Tjoumakaris, Ricardo Hanel, J Mocco, M Ali-Aziz Sultan, Michael Froehler, Barry B Lieber, Alexander Coon, Satoshi Tateshima, David J Altschul, Sandra Narayanan, Kareem El Naamani, Phil Taussky, Brian L Hoh, Philip Meyers, Matthew J Gounis, David S Liebeskind, Victor Volovici, Gabor Toth, Adam Arthur, Ajay K Wakhloo, and ARISE I Consortium
Serial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report., Van-Khue Ton, Song Li, Kevin John, Borui Li, Elric Zweck, Manreet K Kanwar, Shashank S Sinha, Jaime Hernandez-Montfort, A Reshad Garan, Rachel Goodman, Anthony Faugno, Maryjane Farr, Shelley Hall, Rachna Kataria, Maya Guglin, Esther Vorovich, Mohit Pahuja, Saraschandra Vallabhajosyula, Sandeep Nathan, Jacob Abraham, Neil M Harwani, Gavin W Hickey, Andrew D Schwartzman, Wissam Khalife, Claudius Mahr, Ju H Kim, Arvind Bhimaraj, Paavni Sangal, Qiuyue Kong, Karol D Walec, Peter Zazzali, Justin Fried, Daniel Burkhoff, and Navin K Kapur
Patient Time Spent With Professional Medical Interpreters and the Care Experiences of Patients With Limited English Proficiency., Pamela Torresdey, Jacob Chen, and Hector P Rodriguez
Where Did the Oxygen Go?, Julia Townsend, MD
Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today., Howard Trachtman, Hailey Desmond, Amanda L Williams, Laura H Mariani, Sean Eddy, Wenjun Ju, Laura Barisoni, Heather K Ascani, Wendy R Uhlmann, Cathie Spino, Lawrence B Holzman, John R Sedor, Crystal Gadegbeku, Lalita Subramanian, Chrysta C Lienczewski, Tina Manieri, Scott J Roberts, Debbie S Gipson, Matthias Kretzler, NEPTUNE investigators, and Katherine Tuttle (NEPTUNE investigators)
Adoptive cell therapy targeting mutations in gastrointestinal cancers, Eric Tran
Cell transfer therapy targeting oncogenic mutations, Eric Tran
More T cell receptors to the RAScue in cancer?, Eric Tran
Past, Present, and Future of Cellular Immunotherapy, Eric Tran
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings., Steven P Treon, Camille N Kotton, David J. Park, Giorgia Moranzoni, Camilla K Lemvigh, Joseph C Gathe, Tilly A Varughese, Christopher F Barnett, Johnny M Belenchia, Nina M Clark, Charles M Farber, Muhammad Bilal Abid, Gulrayz Ahmed, Christopher J Patterson, Maria L Guerrera, Jacob D Soumerai, Vipheaviny A Chea, Isabel P Carulli, Jackson Southard, Shuqiang Li, Catherine J Wu, Kenneth J Livak, Eric Holmgren, Pil Kim, Carrie Shi, Holly Lin, Vanitha Ramakrishnan, Ying Ou, Scott Olszewski, Lars Rønn Olsen, Derin B Keskin, Zachary R Hunter, Christopher Tankersley, Todd Zimmerman, and Binod Dhakal
Erratum to “Sammie Mosier, DHA, MA, BSN, NE-BC” [Nurse Leader 22/5 (2024) 491-495], Sylvain Trepanier
Leader To Watch: Sammie Mosier, DHA, MA, BSN, NE-BC, Sylvain Trepanier
Safe Staffing Through New Models of Care, Sylvain Trepanier, Kathleen Sanford, Gay Landstrom, Rosalie Mainous, and Susan Bakewell-Sachs
Safe Staffing Through New Models of Care, Sylvain Trepanier, Kathleen Sanford, Gay Landstrom, Rosalie Mainous, and Susan Bakewell-Sachs
Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature., Angela Trobaugh-Lotrario, Kenichiro Watanabe, Allison F O'Neill, Bozenna Dembowska-Bagińska, Beate Häberle, Andrew Murphy, Eiso Hiyama, Piotr Czauderna, Rebecka L Meyers, Max Langham, and James Feusner
Imaging in vasculitis., Orrin M Troum, Olga L Pimienta, and Alvin Wells
Journal names its 25 People of Influence in 2025, Katherine Tuttle (author mention)
379. SGLT Inhibitors: The Biology of SGLT Inhibition with Dr. Katherine Tuttle, Katherine Tuttle
“Adjunctive Therapy in T1D”, Katherine Tuttle
“A Pinch of Salt – A Podcast by ERA”, Katherine Tuttle
“Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status of Risk in the FLOW Trial.", Katherine Tuttle
“Benefits of semaglutide on chronic kidney disease outcomes by cardiovascular status or risk in the FLOW trial.", Katherine Tuttle
“Building your academic career portfolio”, Katherine Tuttle
“Cardiovascular-Kidney-Metabolic Syndrome, Katherine Tuttle
“Cases in Diabetes, Kidney, and Cardio-Renal-Metabolic Disease”, Katherine Tuttle
CKD screening for better kidney health: Why? Who? How? When?, Katherine Tuttle
Clinical and Mechanistic Effects of GLP-1 Receptor Agonists in CKD, Katherine Tuttle
“Diabetic Nephropathy 2024: Comprehensive Care for People with Diabetes Mellitus and Advanced Chronic Kidney Disease.", Katherine Tuttle
“DM and CKD Treatments: Which Treatment Should I Use for Different Populations?”, Katherine Tuttle
“Effects of Semaglutide on CKD in Patients with Type 2 Diabetes (FLOW)”, Katherine Tuttle
“Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.”, Katherine Tuttle
“FLOW: A new treatment paradigm for people with T2D and chronic kidney disease”, Katherine Tuttle
“FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk.”, Katherine Tuttle
“FLOW Result: Summary and Clinical Implication, Katherine Tuttle
“FLOW: Semaglutide scores big in diabetic patients with CKD”, Katherine Tuttle
“ GLP1-RA in CKD”, Katherine Tuttle
GLP-1 Receptor Agonists for CKD in Diabetes and Beyond…, Katherine Tuttle
“GLP-1 Receptor Agonists for CKD in Diabetics and Beyond”, Katherine Tuttle
“Glycemic Management in Persons with Diabetes and CKD”, Katherine Tuttle
“Going with the FLOW: Understanding the renal effects of GLP-1RA Therapy”, Katherine Tuttle
Helio “Aldosterone inhibitor BI 690517 reduced albuminuria when combined with SGLT2 inhibitor”, Katherine Tuttle
Horizons-EASD eLearning, Katherine Tuttle
“How GLP1 receptor agonist evolved from weight management drug to kidney protective therapy”, Katherine Tuttle
“How Will the Incretin Data “FLOW” into Practice?”, Katherine Tuttle
“ Key considerations for tailoring treatment approaches for diabetic patients with chronic kidney disease", Katherine Tuttle
“Kidney Compass Podcast with Drs. Neuen/Wadhwani & Tuttle, Katherine Tuttle
“Kidney Disease and Obesity”, Katherine Tuttle
“Kidney Health for All: Advancing equitable access to care and optimal medication practice”, Katherine Tuttle
“Kidney Week 2024 Press Conference”, Katherine Tuttle
“Kidney Week 2024 Video Interview”, Katherine Tuttle
“Landmark studies”, Katherine Tuttle
“Miracle weight-loss drugs could halt kidney disease too”, Katherine Tuttle
"National Academies Workshop – Preparing the Future Workforce in Drug andResearch Development", Katherine Tuttle
National Geographic Interview feature article, Katherine Tuttle
“Navigating the Sea Change of CKD Treatment in Diabetes”, Katherine Tuttle
“Nephrology Times Interview”, Katherine Tuttle
“New study shows Ozempic lowers kidney disease”, Katherine Tuttle
“New use for Ozempic”, Katherine Tuttle
“Ozempic cuts risk in kidney disease”, Katherine Tuttle
“Ozempic cuts risk of chronic kidney disease complications, study finds””, Katherine Tuttle
“Ozempic keeps wowing: trial data show benefits for kidney disease”, Katherine Tuttle
“Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds", Katherine Tuttle
Plenary - “Kidney Health and CKD Prevention Herald a Sea Change in Nephrology”, Katherine Tuttle
Research Development., Katherine Tuttle
“Sea Change in CKD”, Katherine Tuttle
“Semaglutide cuts kidney failure and death in diabetes”, Katherine Tuttle
“Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial”, Katherine Tuttle
“Semaglutide significantly improves chronic kidney disease”, Katherine Tuttle
“State-of-are Treatment for DKD”, Katherine Tuttle
“State of the art treatment for CKD”, Katherine Tuttle
“Study crystallizes distinct kidney benefits of common drug”, Katherine Tuttle
“Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early.”, Katherine Tuttle
Talk with a Doc Podcast, Katherine Tuttle
The FLOW Trial of Semaglutide for CKD in Type 2 Diabetes: Kidney, Cardiovascular, and Mortality Outcomes, Katherine Tuttle
“The Next Stage: CKM Syndrome Progression and Implications for CVD Outcomes”, Katherine Tuttle
“Therapeutic Transformation of Chronic Kidney Disease”, Katherine Tuttle
“Therapeutic Transformation of Kidney Care – Diabetes and Beyond”, Katherine Tuttle
“Transformation of CKD Care to Delivery Kidney Health”, Katherine Tuttle
“Transforming CKD Care from Evidence Generation to Implementation”, Katherine Tuttle
